Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. - Wikidata - awgldk - TriplyDB

Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

http://www.wikidata.org/entity/Q33959993

about

Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche Regulation and Role of EZH2 in Cancer 3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation.FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy Histone methylases as novel drug targets: developing inhibitors of EZH2.EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.Targeting EZH2 for cancer therapy: progress and perspective.EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis.LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy.Targeting of cancer stem cells by inhibitors of DNA and histone methylation.Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.Recent advances in SCF ubiquitin ligase complex: Clinical implications The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas.Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy

P2860

Q26851166-84527314-B625-4622-8046-8E5C7DDF1C75 Q28543228-4354B73C-3206-47C4-A362-CAAE0BFB61B8 Q34043370-FD073B94-5AF8-42CA-9C19-226828AB3B95 Q34401976-852797E2-9595-4E54-815F-AAF3267F43F4 Q34419383-41E38E84-32EB-490B-99ED-04A398CF00EA Q35059923-5D009242-F61B-448D-A41F-3EB4FBF140D5 Q35147669-552851F7-1DBB-498B-BD0D-6AB0E63375D8 Q35254822-2C5452E0-717F-448E-B4D3-6E5F2239F709 Q35510392-05D5F5F7-4D08-4BE9-A818-BDE79244D8F2 Q35949625-E3E41547-F559-48E0-9305-966B20124608 Q36091288-828A1E9D-F2CC-47DA-A647-1273B5D6C680 Q36539785-6B7DD8CF-4BBC-469E-9F34-FE67024B4860 Q37098331-D99B2AED-A59E-45DB-B0C9-BA44C577CA05 Q37204063-7FEF72F1-E312-4539-8EDE-319F67A20C0C Q37263917-2F285109-DA9C-45DE-896C-4D3D9FAEE6E0 Q37523103-1FC1B683-69CD-43B1-8AE7-26FBEE0CB115 Q37589165-A1756066-8635-46DF-AEEE-55ACF6B39BA4 Q37600907-833B014C-372B-4EA4-8C39-D65D54C10D38 Q38121136-E5A8AF0D-D24C-4ED1-A6EB-69318F42A911 Q38500320-B43B72D1-3DC0-453E-A103-917378E858A5 Q38730980-A7307044-EA45-4E87-AD9B-90D339D2FCE6 Q38828721-516B204F-49C0-49B8-9F01-E66E7AE2C5E6 Q39064876-C2B51BAE-D2C0-4D0B-95FC-32104BEDB1FA Q41612891-E10240C1-F454-432A-9378-8300E1DD9633 Q41625850-8C6F206F-20AD-4C32-9F0C-28C8ECEA1093 Q58725483-AC9C514D-836D-4E95-9636-0A2B7466BB4F

P2860

Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

http://www.wikidata.org/entity/Q33959993

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Superior efficacy of a combine ...... an mantle cell lymphoma cells.

@ast

Superior efficacy of a combine ...... an mantle cell lymphoma cells.

@en

type

label

Superior efficacy of a combine ...... an mantle cell lymphoma cells.

@ast

Superior efficacy of a combine ...... an mantle cell lymphoma cells.

@en

prefLabel

Superior efficacy of a combine ...... an mantle cell lymphoma cells.

@ast

Superior efficacy of a combine ...... an mantle cell lymphoma cells.

@en

P1433

Q33959993-3A30CD7A-1FA3-4FE8-9033-A7C333FBAEC6

P1476

Q33959993-09FBCDA0-4CC7-4F28-B605-F99D0FF96789

P2093

Q33959993-1F9E38FA-6F38-4030-9977-1ACD84EE7669

Q33959993-231A2DDA-53FB-4AE7-BD21-0958C7B844D4

Q33959993-583BB67A-4CB8-4343-B13F-8B64E8FCC721

Q33959993-64F00193-1B10-4BD0-A945-AE6109EBA406

Q33959993-7829CCD8-8E49-42AB-B2EE-95F6B232EC9E

Q33959993-84106491-07DF-4199-A5FB-C3E6F249E70C

Q33959993-84DEA376-4445-4D38-8CA4-EDF57FC71143

Q33959993-9A97287D-A509-4CA8-AB91-794F7132B38C

Q33959993-B9499DE0-98F2-45D6-B2D5-A8E030B5FDEA

Q33959993-FBF36CDC-BB5D-4D35-BA93-94E1DE9EC102

P2860

Q33959993-07C51AE2-9EB3-4B6A-A3CB-AD2CF01FF110

Q33959993-11FA644F-578B-4B04-BEAD-EEB687147A47

Q33959993-1302E6BB-0118-4F36-92D1-21B6E43F65B4

Q33959993-13D50475-972B-406B-8FDF-16BD667BF8D3

Q33959993-19A6C068-FC31-452F-B6C0-A6C41BA8D739

Q33959993-1A3C4E61-3B9A-430A-AD4B-1B61A6A5BA00

Q33959993-20106E5A-A276-417D-9CBB-F3B2E0C15C2F

Q33959993-29B9BE05-4C8B-4690-90D2-1A53CA9E2A26

Q33959993-2B0336B2-14AE-4E21-90AB-DC564A83A501

Q33959993-3A533FAC-B008-4811-BCED-2AD53AD7DCD0

P304

Q33959993-0FEB99B6-99B8-4A30-AC76-97D4D4CC7C55

P31

Q33959993-1460F803-87C0-4C3B-AC47-46FE5AAFE211

P356

Q33959993-152CB538-3FB7-4322-AD44-0FE1D8832E57

P407

Q33959993-E89E69FE-5057-423F-A814-CDE6C18D8C70

P433

Q33959993-ED8B5178-151D-4BF5-B88A-5CBA2501A47D

P478

Q33959993-BEBE127B-39D2-40B0-924E-77BA7CBB85C9

P577

Q33959993-484E6384-F2B9-480D-B7DC-F16CBFDFAC7E

P5875

Q33959993-7215A8EA-FB28-4824-B9A8-4B24E14795A3

P698

Q33959993-2794EAD3-11E0-4302-B090-EC9B9F882D74

P932

Q33959993-7A0B7723-D3BD-4E35-89AE-F877A76619DE

P356

1078-0432.CCR-12-0873

P1433

Clinical Cancer Research

P1476

Superior efficacy of a combine ...... an mantle cell lymphoma cells.

@en

P2093

Eduardo Sotomayor

http://www.w3.org/2001/XMLSchema#string

Jacqueline E Smith

http://www.w3.org/2001/XMLSchema#string

Jianguo Tao

http://www.w3.org/2001/XMLSchema#string

Kapil Bhalla

http://www.w3.org/2001/XMLSchema#string

Peter Atadja

http://www.w3.org/2001/XMLSchema#string

Ramesh Balusu

http://www.w3.org/2001/XMLSchema#string

Rekha Rao

http://www.w3.org/2001/XMLSchema#string

Siddhartha Ganguly

http://www.w3.org/2001/XMLSchema#string

Stacey L Hembruff

http://www.w3.org/2001/XMLSchema#string

Uma Mudunuru

http://www.w3.org/2001/XMLSchema#string

P2860

The Polycomb group protein EZH2 directly controls DNA methylation

DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

The polycomb group protein EZH2 is involved in progression of prostate cancer

Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer

P304

6227-6238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-0873

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230762498

http://www.w3.org/2001/XMLSchema#string

P698

22932665

http://www.w3.org/2001/XMLSchema#string

P932

4113119

http://www.w3.org/2001/XMLSchema#string